Journals / MN Oftalmoloji / 2000 / Cilt: 7 - Sayı: 1

Our first results with dorzolamide 2% in combined treatment of high tension glaucoma

Yüksek basınçlı glokomun kombine tedavisinde %2 dorzolamid ile ilk sonuçlarımız

Pages
31–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

One of its advantages is to reduce number of medications and doses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To evaluate the effects of dorzolamide 2% on lowering intraocular pressure(IOP) and reducing the number of drugs in combined antiglaucomatous theraphy regimen.
📊
Key Findings & Data:MATERIAL AND MEDHODS: Dorzolamide 2% was administered b.i.d to the 39 eyes of 21 high-tension glaucoma patients in combination with other topical antiglaucoma drugs.
💡
Conclusion & Impact:One of its advantages is to reduce number of medications and doses.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kombine tedavi uygulaması · Tedavi sonucu · Betaksolol

Abstract

PURPOSE: To evaluate the effects of dorzolamide 2% on lowering intraocular pressure(IOP) and reducing the number of drugs in combined antiglaucomatous theraphy regimen. MATERIAL AND MEDHODS: Dorzolamide 2% was administered b.i.d to the 39 eyes of 21 high-tension glaucoma patients in combination with other topical antiglaucoma drugs. After a mean follow-up time of 25.2 months, IOPs of the patients, numbers and daily doses of drugs before and after dorzolamide initiating were compared statistically. RESULTS: The reason for dorzolamide initiating was inadequately controlled IOPs with previous medications in 25 eyes, and adverse effects in 14 eyes. Mean IOPs before and after dorzolamide were 19.2±5.02 mmHg and 14.9±2.9mmHg, respectively. Difference was statistically significant (p<0.001). Lowering of IOPs in the inadequately controlled eyes were more significant (21.6±3.7mm Hg before and 15.5±3.4 mmHg after; p<0.001). Mean number of drugs in a patient's regimen were 2.41±0.8 and 2.1010.5, before and after dorzolamide (p<0.001); Number of daily doses were reduced to 5.1±1.4 from 7.2±0.5 (p<0.001). CONCLUSION: Dorzolamide is a new topical carbonic anhydrase inhibitor that could provide increased IOP control. One of its advantages is to reduce number of medications and doses.

Özet

AMAÇ: %2'lik dorzolamidin göz içi basıncını (GİB) düşürmede ve kombine antiglokomatöz tedavide ilaç sayısını azaltmadaki rolünü araştırmak. GEREÇ VE YÖNTEM: GİB diğer antiglokomatöz ilaçlarla regüle edilemeyen hastalardan, tedavilerine günde iki kez %2 dorzolamid eklenen 21 hastanın 39 gözü retrospektif olarak incelendi. Ortalama 25.2 ay takip süreli, tümü yüksek basınçlı glokomu olan hastaların; tanıları, dorzolamid %2 başlanmadan önceki ve sonraki GİB seyirleri, kullandığı ilaçlar ve günlük doz sayıları incelendi. Sonuçlar istatistiksel olarak değerlendirildi. BULGULAR: Tedaviye dorzolamid eklenme nedeni 25 gözde GİB'larının regüle olmaması, 14 gözde ise kontrendikasyon veya komplikasyon nedeniyle ilaçların yeniden düzenlenme gereğiydi. Tüm hastaların GİB ortalaması dorzolamidden önce 19.2±5.02 mmHg, takip sonunda 14.9±2.9mmHg idi; aradaki fark anlamlıydı (p<0.001). Yalnızca GİB regüle olmayan hastaların değerlendirilmesiyle aradaki farkın daha anlamlı hale geldiği görüldü (21.6±3.7 ve 15.5±3.4 mmHg; p<0.001). Dorzolamid ile kombine tedavideki ortalama ilaç sayısı 2.41±0.8'den 2.10±0.5'a indi (p<0.001); günde kullanılan ortalama doz sayısı da azalarak 7.2±0.5'den 5.1±1.4'e düştü (p<0.001). SONUÇ: Dorzolamid, diğer antiglokomatöz ilaçların kullanılamadığı veya yeterli GİB düşmesi sağlayamadığı olgularda başarıyla kullanılabilecek bir topikal karbonik anhidraz inhibitörüdür. Hastanın kullandığı ilaç sayısını ve bir günlük doz sayısını azaltması önemli avantajlarındandır.

🔖

Cite This Article

AKYOL, N., DEMİR, T. (2000). Our first results with dorzolamide 2% in combined treatment of high tension glaucoma. MN Oftalmoloji, Cilt: 7 - Sayı: 1, 31–34. https://ajindex.com/articles/296390

References (14)

  1. Ritch R, Shields MB, Krupin T. Chronic öpen angle glaucoma: treatment. in: The glaucomas. Ritch R, Shields MB, Krupin T, eds. Sec edition. St Louis: Mosby, 1996;1507-17
  2. Wilson MR, Martone JF. Epidemiology of chronic apen angle glaucoma. in: The glaucomas. Ritch R, Shields MB, Krupin T, eds. Sec edition. St Louis: Mosby, 1996;753-68
  3. Stewart WC, Chorak RP, Hunt HH. Factors associated with vısual loss in patients with advanced glaucomatous changes in the optıc nerve head. Am J Ophthalmol 1993; 116:176-81
  4. Serle JB, Podos SM. Topical carbonic anhydrase inhibitors in the treatment glaucoma. OphthalmoİDgy Clinics of North America 1995; 8:315-332
  5. Strahlman E, Tipping R, Vogel R and International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995; 113: 1009-16
  6. Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343-50
  7. Strahlman ER, Vogel R.Tipping R. The use of dorzoiamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Opthalmology 1996; 122: 183-94
  8. Strahlman E, Tipping R, Vogel R. A six week dose response study of the ocular hipotensive effect of dorzolamide with a one year extension. Am J Ophthalmol 1996; 122: 183-94
  9. Laibovitz R, Boyle J, Synder E, Strohmaier K, Adamsons I. Dorzolamide versus pilocarpine as adjunctive therapies to timolol: A comparision patient preference and impact on daily life. ClinTher1996; 18:821-32
  10. James B. Biood flow in the pathogenesis of glaucoma. Current Opinion in Ophthalmology 1993; 4: 65-72
  11. H.Perkins T. Treatment of glaucoma by lowering intraocular pressure. İn: Podos SM, Yonoff M, eds. Textbook of ophthalmology. St Louis: Mosby, 1994; 9:1-9
  12. Strohmaier K, Snyder E, DuBiner H, Adamsons and the Dorzoiamide-Timolol Study Group. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998; 105: 1936-1944
  13. Biollaz J, Munafo A, Buclin T, Gervasoni JP, Magnin JL, Jaque{ F et al. whole blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995;47:453-60
  14. Wang RF, Serle JB, Podos SM, Sugrue MF, MK-507(L-671,152), a topical carbonic anhydrase inhi